Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Trial details
- Registry ID
- NCT06274801
- Drugs studied
- Gereic Dry Powder Inhaler, Seralutinib
TrialRedline tracks 2 clinical trials sponsored by Gossamer Bio USA, Inc.: 1 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)NCT06274801 | Gereic Dry Powder Inhaler, Seralutinib | Recruiting | 2026-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)NCT04816604 | GB002 (seralutinib), Generic Dry Powder Inhaler | Terminated | 2026-09-09Actual |
Names as written in the registry records.
NCT04816604 · Gossamer Bio USA, Inc.
Before: Estimated. After: Actual.
Before: Dec 2027. After: 9 Sep 2026.
Before: Active not recruiting. After: Terminated.
NCT06274801 · Gossamer Bio USA, Inc.
Before: Actual. After: Estimated.
Before: 316 participants (actual). After: 330 participants (planned).
Before: Active not recruiting. After: Recruiting.
NCT06274801 · Gossamer Bio USA, Inc.
Before: Estimated. After: Actual.
Before: 300 participants (planned). After: 316 participants (actual).
Before: Recruiting. After: Active not recruiting.